Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: A prospective analysis of 8 cases

Haematologica

Volumn 96, Issue 7, 2011, Pages 1067-1071

  Trappe, Ralf ^a   Zimmermann, Heiner ^a   Fink, Susanne ^a   Reinke, Petra ^a   Dreyling, Martin ^b   Pascher, Andreas ^a   Lehmkuhl, Hans ^c   Gärtner, Barbara ^d   Anagnostopoulos, Ioannis ^a   Riess, Hanno ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

CD138; Plasmacell lymphoma; Plasmacytoma; Posttransplant lymphoproliferative disorder

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CD20 ANTIGEN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SYNDECAN 1;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BONE LESION; BONE MARROW DISEASE; CANCER SURGERY; CASE STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; EPSTEIN BARR VIRUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MALE; OSTEOLYSIS; PLASMACYTOMA; POST TRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PROSPECTIVE STUDY;

ADULT; AGED; ANTIGENS, CD; B-LYMPHOCYTES; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGAN TRANSPLANTATION; PLASMACYTOMA; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959924235     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.039214     Document Type: Article

References (24)

1. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol. 1997;14(1):8-14.
2. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc. 1969; 1:106-12.
3. Dodd GD 3rd, Greenler DP, Confer SR. Thoracic and abdominal manifestations of lymphoma occurring in the immunocompromised patient. Radiol Clin North Am. 1992;30(3):597-610.
4. Pickhardt PJ, Siegel MJ. Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients. Radiology. 1999;213(1):73-8.
5. Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol. 2001; 19(3):772-8.
6. Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N, et al. Effect of Anti-CD 20 Antibody Rituximab in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD). Am J Transplant. 2005;5 (12):2901-6.
7. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P, et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood. 2006;107:3053-7.
8. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, Gomez-Codina J, Salar A, Bailen A, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica. 2007;92(11):1489-94.
9. Trappe R, Choquet S, Oertel SHK, Leblond V, Dierickx D, Mollee P, et al. Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD-Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial. Blood. 2009;114(22):100.
10. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol.28(6):1038-46.
11. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71(8):1076-88.
12. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporinsteroid therapy. Lancet. 1984;1(8377):583-7.
13. Swinnen LJ, LeBlanc M, Grogan TM, Gordon LI, Stiff PJ, Miller AM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation. 2008;86(2):215-22.
14. Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica. 2007;92 (2):273-4.
15. Meehan SM, Domer P, Josephson M, Donoghue M, Sadhu A, Ho LT, et al. The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies. Hum Pathol. 2001;32 (2):205-15.
16. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995;85(2):552-65.
17. Richendollar BG, Hsi ED, Cook JR. Extramedullary plasmacytoma-like posttransplantation lymphoproliferative disorders: clinical and pathologic features. Am J Clin Pathol. 2009;132(4):581-8.
18. Sun X, Peterson LC, Gong Y, Traynor AE, Nelson BP. Post-transplant plasma cell myeloma and polymorphic lymphoproliferative disorder with monoclonal serum protein occurring in solid organ transplant recipients. Mod Pathol. 2004;17(4):389-94.
19. Gao SZ, Chaparro SV, Perlroth M, Montoya JG, Miller JL, DiMiceli S, et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant. 2003; 22(5):505-14.
20. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis. 2001;3(2):79-87.
21. Green M, Cacciarelli TV, Mazariegos GV, Sigurdsson L, Qu L, Rowe DT, et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation. 1998;66(12):1641-4.
22. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood. 1994;84(3):972-84.
23. Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation. 1995; 60(6):547-54.
24. Ahya VN, Douglas LP, Andreadis C, Arnoldi S, Svoboda J, Kotloff RM, et al. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. J Heart Lung Transplant. 2007;26 (8):839-44.